Part 2. Standards and Schedules

§ 18-18-201. Authority to control

The board shall administer this part 2 and the general assembly, by bill, may add substances to or delete or reschedule substances listed in section 18-18-203, 18-18-204, 18-18-205, 18-18-206, or 18-18-207.

§ 18-18-202. Nomenclature

The controlled substances listed in or to be added to the schedules in sections 18-18-203, 18-18-204, 18-18-205, 18-18-206, and 18-18-207 are listed or added by any official, common, usual, chemical, or trade name used.

§ 18-18-203. Schedule I

(1) A substance shall be added to schedule I by the general assembly when:
(a) The substance has high potential for abuse;
(b) The substance has no currently accepted medical use in treatment in the United States; and
(c) The substance lacks accepted safety for use under medical supervision.
(2) Unless specifically excepted by Colorado or federal law or Colorado or federal regulation or more specifically included in another schedule, the following controlled substances are listed in schedule I:
(a) Any of the following synthetic opiates, including any isomers, esters, ethers, salts, and salts of isomers, esters, and ethers of them that are theoretically possible within the specific chemical designation:
(I) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl ] -N- phenylacetamide);
(II) Acetylmethadol;
(III) Allylprodine;
(IV) Alphacetylmethadol;
(V) Alphameprodine;
(VI) Alphamethadol;
(VII) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)- 4-(N-propanilido) piperidine);
(VIII) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl) ethyl-4-piperidinyl]-N-phenylpropanamide);
(IX) Benzethidine;
(X) Betacetylmethadol;
(XI) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- piperidinyl]-N-phenylpropanamide);
(XII) Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl-] N-phenylpropanamide);
(XIII) Betameprodine;
(XIV) Betamethadol;
(XV) Betaprodine;
(XVI) Clonitazene;
(XVII) Dextromoramide;
(XVIII) Diampromide;
(XIX) Diethylthiambutene;
(XX) Difenoxin;
(XXI) Dimenoxadol;
(XXII) Dimepheptanol;
(XXIII) Dimethylthiambutene;
(XXIV) Dioxaphetyl butyrate;
(XXV) Dipipanone;
(XXVI) Ethylmethylthiambutene;
(XXVII) Etonitazene;
(XXVIII) Etoxeridine;
(XXIX) Furethidine;
(XXX) Hydroxypethidine;
(XXXI) Ketobemidone;
(XXXII) Levomoramide;
(XXXIII) Levophenacylmorphan;
(XXXIV) 3-methylfentanyl (N-[3-methyl-1-(2- phenylethyl)-4-piperidyl]-N-phenylpropanamide);
(XXXV) 3-methylthiofentanyl (N-[3-methyl-1-(2- thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
(XXXVI) Morpheridine;
(XXXVII) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
(XXXVIII) Noracymethadol;
(XXXIX) Norlevorphanol;
(XL) Normethadone;
(XLI) Norpipanone;
(XLII) Para-fluorofentanyl (N-(4-fluorophenyl)-N- [1-(2-phenethyl) -4-piperidinyl]-propanamide);
(XLIII) PEPAP (1-(-2-phenethyl)-4-phenyl- 4-acetoxypiperidine);
(XLIV) Phenadoxone;
(XLV) Phenampromide;
(XLVI) Phenomorphan;
(XLVII) Phenoperidine;
(XLVIII) Piritramide;
(XLIX) Proheptazine;
(L) Properidine;
(LI) Propiram;
(LII) Racemoramide;
(LIII) Thiofentanyl (N-phenyl-N-[1-(2- thienyl) ethyl-4-piperidinyl]-propanamide);
(LIV) Tilidine;
(LV) Trimeperidine.
(b) Any of the following opium derivatives, including their salts, isomers, and salts of isomers of them that are theoretically possible within the specific chemical designation:
(I) Acetorphine;
(II) Acetyldihydrocodeine;
(III) Benzylmorphine;
(IV) Codeine methylbromide;
(V) Codeine-N-Oxide;
(VI) Cyprenorphine;
(VII) Desomorphine;
(VIII) Dihydromorphine;
(IX) Drotebanol;
(X) Etorphine, except hydrochloride salt;
(XI) Heroin;
(XII) Hydromorphinol;
(XIII) Methyldesorphine;
(XIV) Methyldihydromorphine;
(XV) Morphine methylbromide;
(XVI) Morphine methylsulfonate;
(XVII) Morphine-N-Oxide;
(XVIII) Myrophine;
(XIX) Nicocodeine;
(XX) Nicomorphine;
(XXI) Normorphine;
(XXII) Pholcodine;
(XXIII) Thebacon.
(c) Any material, compound, mixture, or preparation containing any quantity of the following hallucinogenic substances, including any salts, isomers, and salts of isomers of them that are theoretically possible within the specific chemical designation:
(I) 4-bromo-2, 5-dimethoxy-amphetamine (Some trade or other names: 4-bromo-2, 5-dimethoxy-alpha- methylphenethylamine; 4-bromo-2, 5-DMA.);
(II) 2,5-dimethoxyamphetamine (Some trade or other names: 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA.);
(II.5) 2,5-Dimethoxy-4-ethylamphetamine (DOET);
(III) 4-methoxyamphetamine (Some trade or other names: 4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine, PMA.);
(IV) 5-methoxy-3,4-methylenedioxy amphetamine;
(IV.5) 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DiPT);
(V) 4-methyl-2,5-dimethoxy-amphetamine (Some trade and other names: 4-methyl-2,5-dimethoxy-alpha- methylphenethylamine; DOM; and STP.);
(VI) 3,4-methylenedioxy amphetamine;
(VII) 3,4-methylenedioxymethamphetamine (MDMA);
(VIII) 3,4,5-trimethoxy amphetamine;
(VIII.5) Alpha-methyltryptamine (AMT);
(IX) Bufotenine (Some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2- dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine.);
(X) Diethyltryptamine (Some trade or other names: N,N-Diethyltryptamine; DET.);
(XI) Dimethyltryptamine (Some trade or other names: DMT.);
(XII) Ibogaine (Some trade and other names: (7-Ethyl-6,6B,7,8,9,10,12,13-octahydro-2- methoxy-6,9-methano-5H-pyrido [1’, 2’:1,2] azepine [5,4- b] indole; Tabernanthe iboga.);
(XIII) Lysergic acid diethylamide;
(XIV) Mescaline;
(XV) Parahexyl (Some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran; Synhexyl.);
(XVI) Peyote (Meaning all parts of the plant classified botanically as Lophophora williamsii Lemaire, whether growing or not, its seeds, any extract from any part of the plant, and every compound, salt, derivative, mixture, or preparation of the plant, or its seeds or extracts);
(XVII) N-ethyl MDA;
(XVIII) N-ethyl-3-piperidyl benzilate;
(XIX) N-hydroxy MDA;
(XX) N-methyl-3-piperidyl benzilate;
(XXI) Psilocybin;
(XXII) Psilocyn;
(XXIII) Tetrahydrocannabinols;
(XXIV) Ethylamine analog of phencyclidine (Some trade or other names: N-ethyl-1- phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexl) ethylamine, cyclohexamine, PCE.);
(XXV) Pyrrolidine analog of phencyclidine (Some trade or other names: 1-(1-phenylcyclohexyl)- pyrrolidine, PCPy, PHP.);
(XXVI) Thiophene analog of phencyclidine (Some trade or other names: 1-]1-(2-thienyl)-cyclohexyl- piperidine, 2-thienyl analog of phencyclidine, TPCP, TCP.);
(XXVII) TCPy.
(d) Any material, compound, mixture, or preparation containing any quantity of the following substances having a depressant effect on the central nervous system, including any salts, isomers, and salts of isomers of them that are theoretically possible within the specific chemical designation:
(I) Mecloqualone;
(II) Methaqualone.
(e) Any material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, and salts of isomers:
(I) Repealed.
(II) Fenethylline;
(III) Methcathinone;
(IV) N-ethylamphetamine;
(V) +) Cis-4-methylaminorex;
(VI) N,N-dimethylamphetamine.
(f) Any material, compound, mixture, or preparation containing any quantity of gamma hydroxybutyrate [GHB], including its salts, isomers, and salts of isomers.
(g) Any material, compound, mixture, or preparation which is a controlled substance analog, the chemical structure of which is substantially similar to the chemical structure of a controlled substance listed in this subsection (2) or that was specifically designed to produce an effect substantially similar to or greater than the effect of a controlled substance listed in this subsection (2), all or part of which is intended for human consumption.
(h) Any material, compound, mixture, or preparation containing any quantity of N-benzylpiperazine (BZP), including its salts, isomers, and salts of isomers.

§ 18-18-204. Schedule II

(1) A substance shall be added to schedule II by the general assembly when:
(a) The substance has high potential for abuse;
(b) The substance has currently accepted medical use in treatment in the United States, or currently accepted medical use with severe restrictions; and
(c) The abuse of the substance may lead to severe psychological or physical dependence.
(2) Unless specifically excepted by Colorado or federal law or Colorado or federal regulation or more specifically included in another schedule, the following controlled substances are listed in schedule II:
(a) Any of the following substances, however manufactured:
(I) Opium and opium derivative, and any salt, compound, derivative, or preparation of opium or opium derivative, excluding apomorphine, dextrorphan, nalbuphine, butorphanol, nalmefene, naloxone, and naltrexone, but including:
(A) Raw opium;
(B) Opium extracts;
(C) Opium fluid;
(D) Powdered opium;
(E) Granulated opium;
(F) Tincture of opium;
(G) Codeine;
(H) Ethylmorphine;
(I) Etorphine hydrochloride;
(J) Hydrocodone;
(K) Hydromorphone;
(L) Metopon;
(M) Morphine;
(N) Oxycodone;
(O) Oxymorphone;
(P) Thebaine.
(II) Any salt, compound, derivative, or preparation that is chemically equivalent or identical with any of the substances listed in subparagraph (I) of this paragraph (a), but not isoquinoline alkaloids of opium;
(III) Opium poppy and poppy straw;
(IV) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, including cocaine and ecgonine and their salts, isomers, derivatives, and salts of isomers and derivatives, and any salt, compound, derivative, or preparation that is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves which do not contain cocaine or ecgonine;
(V) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy).
(b) Any of the following synthetic opiates, including any isomers, esters, ethers, salts, and salts of isomers, esters, and ethers of them that are theoretically possible within the specific chemical designation:
(I) Alfentanil;
(II) Alphaprodine;
(III) Anileridine;
(IV) Benzitramide;
(V) Carfentanal;
(VI) Dihydrocodeine;
(VII) Diphenoxylate;
(VIII) Fentanyl;
(IX) Isomethadone;
(IX.5) Levo-alphacetylmethadol;
(X) Levomethorphan;
(XI) Levorphanol;
(XII) Metazocine;
(XIII) Methadone;
(XIV) Methadone - Intermediate, 4-cyano-2- dimethylamino-4, 4-diphenyl butane;
(XV) Moramide - Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid;
(XVI) Pethidine (meperidine);
(XVII) Pethidine - Intermediate-A, 4-cyano-1- methyl-4-phenylpiperidine;
(XVIII) Pethidine - Intermediate-B, ethyl-4- phenylpiperidine-4-carboxylate;
(XIX) Pethidine - Intermediate-C, 1-methyl- 4-phenylpiperidine-4-carboxylic acid;
(XX) Phenazocine;
(XXI) Piminodine;
(XXII) Propoxyphene (non-dosage forms);
(XXIII) Racemethorphan;
(XXIV) Racemorphan;
(XXV) Sufentanil.
(c) Any material, compound, mixture, or preparation containing any quantity of the following substances, their salts, isomers, or salts of isomers, having a stimulant effect on the central nervous system:
(I) Amphetamine;
(II) Methamphetamine;
(III) Phenmetrazine;
(IV) Methylphenidate.
(d) Any material, compound, mixture, or preparation containing any quantity of the following substances having a depressant effect on the central nervous system, including any salts, isomers, and salts of isomers of them that are theoretically possible within the specific chemical designation:
(I) Amobarbital;
(II) Pentobarbital;
(III) Phencyclidine;
(IV) Secobarbital;
(V) Glutethimide.
(e)
(I) Repealed.
(II) Nabilone [Another name for nabilone: (+) trans-3-(1,1-demethylheptyl)-6,6a,7,8,10, 10a-hexahydro- 1-hydroxy-6,6-dimethyl-9Hdibenzo [b,d] pyran-9-one].
(f) Any material, compound, mixture, or preparation containing any quantity of the following substances:
(I) Immediate precursor to amphetamine and methamphetamine: phenylacetone (Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone.), ephedrine, alpha-phenylacetoacetonitrile, phenylacetic acid, and 1-phenyl-2-nitropropene;
(II) Immediate precursors to phencyclidine:
(A) 1-phenylcyclohexylamine;
(B) 1-piperidinocyclohexanecarbonitrile (PCC);
(C) Piperdine;
(D) Morpholine;
(E) Pyrrolidine;
(III) Remifentanil hydrochloride.
(g) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which is a controlled substance analog, as defined in section 18-18-102 (6), the chemical structure of which is substantially similar to the chemical structure of a controlled substance in schedule II of this part 2 or that was specifically designed to produce an effect substantially similar to or greater than the effect of a controlled substance in schedule II of this part 2, all or part of which is intended for human consumption, shall be treated for the purposes of this article as a controlled substance in schedule II of this part 2.

§ 18-18-205. Schedule III

(1) A substance shall be added to schedule III by the general assembly when:
(a) The substance has a potential for abuse less than the substances included in schedules I and II;
(b) The substance has currently accepted medical use in treatment in the United States; and
(c) The abuse of the substance may lead to moderate or low physical dependence or high psychological dependence.
(2) Unless specifically excepted by Colorado or federal law, or Colorado or federal regulation, or more specifically included in another schedule, the following controlled substances are listed in schedule III:
(a) Any material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including any salts, isomers, and salts of isomers of them that are theoretically possible within the specific chemical designation:
(I) Any compound, mixture, or preparation in dosage unit form containing any stimulant substance included in schedule II and which was listed as an excepted compound on August 25, 1971, pursuant to the federal “Controlled Substances Act”, and any other drug of the quantative composition shown in that list for those drugs or which is the same except for containing a lesser quantity of controlled substances;
(II) Benzphetamine;
(III) Chlorphentermine;
(IV) Clortermine;
(V) Phendimetrazine.
(b) Any material, compound, mixture, or preparation containing any quantity of the following substances having a depressant effect on the central nervous system:
(I) Any compound, mixture, or preparation containing any of the following drugs or their salts and one or more other active medicinal ingredients not included in any schedule:
(A) Amobarbital;
(B) Secobarbital;
(C) Pentobarbital;
(II) Any of the following drugs, or their salts, in suppository dosage form, approved by the federal food and drug administration for marketing only as a suppository:
(A) Amobarbital;
(B) Secobarbital;
(C) Pentobarbital;
(III) Any substance containing any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid;
(IV) Chlorhexadol;
(V) Lysergic acid;
(VI) Lysergic acid amide;
(VII) Methyprylon;
(VIII) Sulfondiethylmethane;
(IX) Sulfonethylmethane;
(X) Sulfonmethane;
(XI) Tiletamine and zolazepam or any of their salts (Some trade or other names for a tiletamine-zolazepam combination product: Telazol. Some trade or other names for tiletamine: 2-(ethylamino)-2-(2- thienyl)-cyclohexanone. Some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one. flupyrazapon.).
(c) Nalorphine;
(d) Any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as follows:
(I) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
(II) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(III) Not more than 300 milligrams of hydrocodone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
(IV) Not more than 300 milligrams of hydrocodone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(V) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(VI) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(VII) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(VIII) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(e) Anabolic steroids.
(f) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a federal food and drug administration approved drug product [Other names for dronabinol: (6aR-trans)-6a,7,8,10a- tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo [b,d] pyran-1-o1, or (-)-delta-9-(trans)-tetrahydrocannabinol];
(g) Ketamine, its salts, isomers, and salts of isomers [Other names for ketamine: (+)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone].
(3) The board may exempt by rule a compound, mixture, or preparation containing any stimulant or depressant substance listed in paragraph (a) or (b) of subsection (2) of this section from the application of all or part of this article if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system and if the admixtures are in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances having a stimulant or depressant effect on the central nervous system.

§ 18-18-206. Schedule IV - repeal

(1) A substance shall be added to schedule IV by the general assembly when:
(a) The substance has a low potential for abuse relative to substances included in schedule III;
(b) The substance has currently accepted medical use in treatment in the United States; and
(c) The abuse of the substance may lead to limited physical dependence or psychological dependence relative to the substances included in schedule III.
(2) Unless specifically excepted by Colorado or federal law or Colorado or federal regulation or more specifically included in another schedule, the following controlled substances are listed in schedule IV:
(a) Any material, compound, mixture, isomers or salts or isomers, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as follows:
(I) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit;
(II) Propoxyphene (dosage forms);
(III) Butorphanol;
(b) Any material, compound, mixture, or preparation containing any quantity of the following substances having a depressant effect on the central nervous system, including any salts, isomers, and salts of isomers of them that are theoretically possible within the specific chemical designation:
(I) Alprazolam;
(II) Barbital;
(III) Bromazepam;
(IV) Camazepam;
(V) Chloral betaine;
(VI) Chloral hydrate;
(VII) Chlordiazepoxide;
(VIII) Clobazam;
(IX) Clonazepam;
(X) Clorazepate;
(XI) Clotiazepam;
(XII) Cloxazolam;
(XIII) Delorazepam;
(XIV) Diazepam;
(XV) Estazolam;
(XVI) Ethchlorvynol;
(XVII) Ethinamate;
(XVIII) Ethyl loflazepate;
(XIX) Fludiazepam;
(XX) Flunitrazepam;
(XXI) Flurazepam;
(XXII) Halazepam;
(XXIII) Haloxazolam;
(XXIV) Ketazolam;
(XXV) Loprazolam;
(XXVI) Lorazepam;
(XXVII) Lormetazepam;
(XXVIII) Mebutamate;
(XXIX) Medazepam;
(XXX) Meprobamate;
(XXXI) Methohexital;
(XXXII) Methylphenobarbital (mephobarbital);
(XXXIII) Midazolam;
(XXXIV) Nimetazepam;
(XXXV) Nitrazepam;
(XXXVI) Nordiazepam;
(XXXVII) Oxazepam;
(XXXVIII) Oxazolam;
(XXXIX) Paraldehyde;
(XL) Petrichloral;
(XLI) Phenobarbital;
(XLII) Pinazepam;
(XLIII) Prazepam;
(XLIV) Quazepam;
(XLV) Temazepam;
(XLVI) Tetrazepam;
(XLVII) Triazolam;
(XLVIII) Zolpidem;
(c)
(I) Any material, compound, mixture, or preparation containing any quantity of the following substance, including any salts, isomers of it that are theoretically possible: Fenfluramine.
(II) This paragraph (c) is repealed upon removal of fenfluramine and its salts and isomers from schedule IV of the federal “Controlled Substances Act” (21 U.S.C. sec. 812; 21 CFR 1308.14).
(d) Any material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, and salts of isomers:
(I) Cathine;
(II) Diethylpropion;
(III) Fencamfamin;
(IV) Fenpropore;
(V) Mazindol;
(VI) Pemoline (including organometallic complexes and chelates thereof);
(VII) Phentermine;
(VIII) Pipradrol;
(IX) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
(e) Any material, compound, mixture, or preparation containing any quantity of the following substances, including their salts and isomers:
(I) Modafinil;
(II) Pentazocine;
(III) Sibutramine;
(IV) Stadol (butorphanol tartrate);
(f) Zaleplon.
(3) The board may exempt by rule any compound, mixture, or preparation containing any depressant substance listed in paragraph (b) of subsection (2) of this section from the application of all or any part of this article if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances having a depressant effect on the central nervous system.

§ 18-18-207. Schedule V

(1) A substance shall be added to schedule V by the general assembly when:
(a) The substance has a low potential for abuse relative to substances included in schedule IV;
(b) The substance has currently accepted medical use in treatment in the United States; and
(c) The abuse of the substance may lead to limited physical dependence or psychological dependence relative to the substances included in schedule IV.
(2) Unless specifically excepted by Colorado or federal law or Colorado or federal regulation or more specifically included in another schedule, the following controlled substances are listed in schedule V:
(a) Any material, compound, mixture, or preparation containing any of the following narcotic drug and its salts: Buprenorphine;
(b) Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth in this paragraph (b), which also contains one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
(I) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
(II) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
(III) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
(IV) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;
(V) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
(VI) Not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit;
(c) Any material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, and salts of isomers: Pyrovalerone.